Estrogen binds to ESR1, enhancing T cell activation, promoting immune surveillance, and improving treatment responses in females. ESR1 expression may serve as a predictive biomarker for immunotherapy responsiveness in female HCC patients. Here, ESR1 is linked to hepatocellular carcinoma.